Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Wang Zhenghong	2. Date of Event Requiring Statement (MM/DD/YYYY) 3/26/2012	3. Issuer Name and Ticker or Trading Symbol Biostar Pharmaceuticals, Inc. [BSPM]
(Last)        (First)        (Middle) C/O BIOSTAR PHARMACEUTICALS, INC., NO. 588 SHIJI AVENUE	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                            _____ 10% Owner ___ X ___ Officer (give title below)          _____ Other (specify below) Chief Operating Officer /
(Street) XIANYANG, F4 712046        (City)              (State)              (Zip)	5. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock   (1)	10/22/2009	10/21/2014	Common stock	6667	$7.8	D

Explanation of Responses:

( 1)

This option was issued pursuant to the Company's 2009 Incentive Stock Plan and Incentive Stock Option Agreement dated as of October 22, 2009. On a post reverse split basis, the number of shares purchasable under this option is adjusted to 6,667 shares and its exercise price is adjusted to $7.80. The option shall become exercisable during the term of the Reporting Person's employment in three equal annual installments, the first installment to be exercisable on the date of grant (the "Initial Vesting Date"), with additional installments becoming exercisable on each of the successive anniversaries following the Initial Vesting Date.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Wang Zhenghong C/O BIOSTAR PHARMACEUTICALS, INC. NO. 588 SHIJI AVENUE XIANYANG, F4 712046			Chief Operating Officer

Signatures
/s/ Zhenghong Wang		4/15/2013
** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.